Table 4.
Clinical characteristics of patients between asthma and asthma-COPD overlap
| Asthma | ACO | p value | |
|---|---|---|---|
| N | 103 | 129 | |
| Sex (M/F) | 52/65 | 56/58 | 0.476 |
| Age (y) | 42 ± 14 | 56 ± 8 | < 0.001 |
| BMI | 24.1 ± 3.7 | 23.7 ± 3.0 | 0.664 |
| NA, N (%) | 4 (40%) | 6 (60%) | 0.514 |
| EA, N (%) | 45 (50.6%) | 44 (49.4%) | 0.514 |
| MGA, N (%) | 4 (33.3%) | 8 (66.7%) | 0.514 |
| PGA, N (%) | 64 (53.3%) | 56 (46.7%) | 0.514 |
| Smoking history | < 0.001 | ||
| Never smoker, N (%) | 80 (68.4%) | 53 (46.5%) | |
| Current smoker, N (%) | 13 (11.1%) | 36 (31.6%) | |
| Ex-smoker, N (%) | 24 (20.5%) | 25 (21.9%) | |
| Pack-years | 0 (0, 3.3) | 5.2 (0, 25.0) | < 0.001 |
| Diagnosis age (y) | 38 ± 13 | 50 ± 12 | < 0.001 |
| Asthma diagnosed more than 1 year, N (%) | 59 (53.6%) | 75 (69.4%) | 0.016 |
| Severe asthma, N (%) | 48 (42.1%) | 41 (37.6%) | 0.494 |
| Atopy (Y/N) | 19/34 | 18/47 | 0.342 |
| ICS dose | 0 (0, 400) | 250 (0, 400) | 0.032 |
| Post-FEV1/FVC, % | 77.7 ± 8.8 | 58.0 ± 8.9 | < 0.001 |
| Post-FEV1% predicted | 93.5 ± 19.9 | 69.7 ± 21.2 | < 0.001 |
| FeNO (ppd) | 42.5 (23.3, 88.9) | 39.2 (22.9, 63.4) | 0.249 |
| ACQ6 | 1.4 (0.5, 2.1) | 1.5 (0.7, 2.2) | 0.020 |
| ACT | 18.0 (14.0, 22.0) | 16.0 (13.0, 20.0) | 0.010 |
| Global AQLQ | 5.2 (4.2, 6.1) | 5.0 (4.2, 5.8) | 0.081 |
| HAD | 3.5 (0.0, 10.0) | 2.0 (0.0, 10.0) | 0.476 |
| Blood eosinophils, 109/L | 0.3 (0.1, 0.5) | 0.2 (0.1, 0.6) | 0.792 |
| Blood neutrophils, 109/L | 4.6 (3.9, 5.8) | 3.7 (3.2, 5.0) | 0.429 |
| Blood lymphocytes, 109/L | 2.0 (1.5, 2.5) | 2.1 (1.8, 2.8) | 0.089 |
| Blood monocytes, 109/L | 0.5 (0.4, 0.6) | 0.5 (0.4, 0.7) | 0.021 |
| Sputum TCC (106/mL) | 2.7 (1.0, 5.0) | 3.0 (1.9, 5.7) | 0.031 |
| Sputum macrophages, % | 86.0 (59.7, 96.5) | 82.0 (49.9, 93.7) | 0.092 |
| Sputum neutrophils, % | 0.75 (0.0, 5.2) | 1.6 (0.0, 11.5) | 0.024 |
| Sputum eosinophils, % | 1.9 (0.3, 7.9) | 2.5 (0.4, 7.5) | 0.908 |
| Sputum lymphocytes, % | 1.3 (0.5, 3.8) | 2.1 (0.5, 5.7) | 0.184 |
Data are presented as mean ± SD or median (IQR), unless otherwise indicated
ACO Asthma-COPD overlap, NA neutrophilic asthma, EA eosinophilic asthma, MGA mixed granulocytic asthma, PGA paucigranulocytic asthma, IQR interquartile range